| Filed On | Filing |
|---|---|
| 23 Oct 2026 | AMENDMENT NO. 1 TO FORM SC TO-I |
| 19 Oct 2026 | Proxy statement: special meeting on November 13, 2026 |
| 15 Oct 2026 |
8-K: Other Events
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy |
| 14 Oct 2026 | REGISTRATION STATEMENT |
| 09 Oct 2026 | PROXY STATEMENT |
| 07 Oct 2026 |
8-K: Other Events
REDWOOD CITY, Calif., October 7, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat ... |
| 07 Oct 2026 | FORM SC TO-I |
| 05 Oct 2026 |
8-K/A: Financial Statements and Exhibits
For the Six Months Ended June 30, 2026 and the Year Ended December 31, 2025 |
| 05 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 30, 2026, Jasper Therapeutics, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, a total of 21,747,865 shares of the Company’s voting common stock, $0.0001 par value... |
| 01 Oct 2026 |
8-K/A: Financial Statements and Exhibits
Consolidated Statements of Operations and Comprehensive Loss |
| 28 Sep 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Jasper Therapeutics, Inc. (the... |
| 24 Sep 2026 | 25-NSE |
| 04 Sep 2026 | Proxy statement: special meeting on September 30, 2026 |
| 26 Aug 2026 | 8-K: Entry into a Material Definitive Agreement |
| 24 Aug 2026 | PROXY STATEMENT |
| 17 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 14 Aug 2026 | QUARTERLY REPORT |
| 05 Aug 2026 | D |
| 04 Aug 2026 |
Form 4: Wiggans Thomas G, Director
Granted 7,500 Stock Option (Right to Buy |
Loading...
